Acute Effects of Protein Ingestion on Bone Turnover Biomarkers in Endurance Runners
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Beta-C-terminal telopeptide
研究概览
简要总结
The goal of this clinical trial is to investigate the effects of protein ingestion post-exercise on bone turnover markers. The main questions it aims to answer is:
Does protein ingestion independently influence the bone metabolic response to exercise in endurance runners?
We will compare dietary protein to a placebo (water) to detect changes in bone turnover markers.
Participants will:
In a within-subject design, participants will perform an exhaustive run and take either protein or placebo immediately post-exercise.
Track physical activity and diet before each arm of the intervention and during the washout period.
详细描述
Endurance athletes are at increased risk for bone loss and injury due to high-volume training, muscle weakness, and elevated nutritional demand. Dietary practices influence short- and long-term bone health and nutrition supplementation post-exercise may improve the short-term response of bone to exercise and benefit musculoskeletal recovery. However, we have a limited understanding of which dietary practices are most beneficial to optimize bone health in athletic populations. Protein supplementation has long been recommended for muscle adaptation and athletic performance but its potential for bone health has not been thoroughly investigated in endurance athletes. The purpose of this study is to is to investigate the acute independent effects of dietary protein ingestion on bone metabolism in healthy adults aged 18-35 years participating in high-volume endurance running.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18-35 years of age
- •Healthy-range body mass index (BMI) (18.5-24.9 kg/m2)
- •Competitive runner for at least one season (minimum 40 km/week for the past 6-months)
- •Can read, speak, and understand French and/or English
排除标准
- •Disease or medication known to affect bone metabolism
- •Disease (e.g., uncontrolled thyroid disease, malabsorptive or inflammatory disorder, metabolic bone disease)
- •Medication (e.g., hormonal contraceptives the past 3 months, glucocorticoids, anti-hypertensive drugs, anti-epileptic drugs, osteoporosis therapy)
- •Orthopedic or musculoskeletal injury/disease that limits the capacity to exercise
- •Current smoker or tobacco user
- •Current diagnosis of an eating disorder
- •Female participants with self-reported or diagnosed:
- •Hypothalamic amenorrhea
- •Polycystic ovarian syndrome
- •Hyperprolactinemia
- •Primary ovarian insufficiency
- •Pregnant or breastfeeding
- •Donated blood within the past two months
结局指标
主要结局
Beta-C-terminal telopeptide
时间窗: Up to 24 hours
Bone resorption marker
Procollagen 1 Intact N-Terminal Propeptide
时间窗: Up to 24 hours
Bone formation marker
次要结局
- Insulin-like growth factor 1(Up to 24 hours)
- Sclerostin(Up to 24 hours)
- OPG(Up to 24 hours)
- RANK/RANKL(Up to 24 hours)
- IL-6(Up to 24 hours)
研究者
Jenna Gibbs
Dr. Jenna Gibbs, Assistant Professor
McGill University